Apple
AAPL
Taylor Morrison Home
TMHC
D.R. Horton
DHI
Petroleo Brasileiro SA Petrobras
PBR
Vale SA
VALE
US Stock MarketDetailed Quotes
EYPT EyePoint Pharmaceuticals
- 5.910
- -0.150-2.48%
Close Mar 27 16:00 ET
- 5.910
- 0.0000.00%
Post 16:24 ET
406.19MMarket Cap-2.55P/E (TTM)
6.250High5.900Low606.77KVolume6.100Open6.060Pre Close3.67MTurnover1.39%Turnover RatioLossP/E (Static)68.73MShares23.64552wk High1.21P/B257.34MFloat Cap5.54052wk Low--Dividend TTM43.54MShs Float72.200Historical High--Div YieldTTM5.78%Amplitude2.190Historical Low6.051Avg Price1Lot Size
Market Insights
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
EyePoint Pharmaceuticals Stock Forum
EyePoint Reports Mixed Earnings: Can Its $371M War Chest and Promising Eye Disease Pipeline Deliver Returns?
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept...
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds
EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses
No comment yet